3:00 PM
 | 
Mar 02, 2017
 |  BC Week In Review  |  Clinical News  |  Regulatory

Pemetrexed RTD regulatory update

FDA accepted an NDA from Eagle for pemetrexed RTD as monotherapy to treat locally advanced or metastatic non-squamous non-small...

Read the full 72 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >